Protagonist TherapeuticsPTGX
Recorded

Protagonist Therapeutics Jefferies Global Healthcare Conference in London

Review the key takeaways and the transcript of this earnings call.

Period 0Duration26 minParticipants2

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Roger SongSenior Analyst

All right. Welcome, everyone, to Jefferies 2026 Global Healthcare Conference in London. My name is Roger Song, senior analyst, covers biotech in the U.S. It is my pleasure to have the fireside chat with our next company, Protagonist Therapeutics, and we have the CEO, Dinesh Patel.

Dinesh PatelCEO

Welcome, Dinesh. Always a pleasure to be here and to have a conversation with you, Roger.

Roger SongSenior Analyst

Excellent. All right, why don't you just start with the brief overview of Protagonist, which is in a very enviable position right now. So give us a minute or two.

Dinesh PatelCEO

Yeah, I mean, it has been a long journey, but finally we have arrived at a very good place, a very unique place. At one end, we kind of are a company with two approved drugs, so we have entered into the, quote-unquote, "commercial space," but without hiring a single salesforce person. That is by virtue of the two amazing partnerships that we did, the right kind of partnership at the right time, one with J&J, the other with Takeda.

Dinesh PatelCEO

Now, of course, the benefit of all that is you are validated, you and the team have this amazing satisfaction at the core level of having contributed two drugs that will make a difference in the life of patients, and you also get a very steady stream of revenue, which then in turn allows you to fund your own R&D engine without bad news for the bankers, going out and trying to raise money. On top of that, we believe the flow of money will be of such magnitude that from time to time, we should also be able to do share buybacks. So, it is like compressing a lot in a single company, but I think these are all positives, and we believe this is just the beginning.

Dinesh PatelCEO

The mastery that we have over the peptide technology platform is going to enable us to do wonderful things, as is reflected by our very thriving R&D pipeline.

Roger SongSenior Analyst

Excellent. Okay. Then, as you said, you have two commercial products through two major pharma partners, and then everyone very focused on ICOTYDE, and then MIMRYLO also launching out pretty nicely. So for ICOTYDE, J&J is on the driver's seat, and then how much you can say about the revenue and then royalty trending, and then when, if you will break up, then maybe next year?

Dinesh PatelCEO

Yeah. So, I mean, clearly, ICOTYDE has gotten a very high level of visibility, and maybe rightfully so. As you know, it also got nominated as one of the best innovative medicines by TIME Magazine.

Dinesh PatelCEO

I saw that which is very satisfying for the scientific souls.

Dinesh PatelCEO

Commercially, I mean, if you just look at the qualitative statements from J&J executives, right? I mean, the launch is almost at an unprecedented scale of more than 20,000 prescriptions already, as reported by J&J during their earnings call. Also a very nice distribution of 60% are systemic naive, but 20% are switching from orals, and this is for psoriasis, obviously, and the other 20% are switching from injectables.

Dinesh PatelCEO

Yeah. This is a great beginning.

Dinesh PatelCEO

Now, in terms of the precision of revenues and all that, we will follow J&J's lead. We don't want to outrun them, and I believe during their earnings call, they guided towards breaking it down as a line item sometime in 2027.

Roger SongSenior Analyst

Okay. Mm-hmm. Yeah, got it. Before that, I'm going to keep using my estimate.

Dinesh PatelCEO

Fair enough. Yes. Yeah. I mean, we do have a good chunk of over half a billion of milestones also that are pending, and in theory, we believe all of those could be achievable because the development milestones are geared towards second and third indications, NDA filings and approval, and the sales milestones, we don't believe the highest hurdle is if it crosses over a $5 billion mark in a given year.

Roger SongSenior Analyst

Mm-hmm. Got it. Okay, great. Obviously, they keep expanding the indication into PsA. We just saw the data at the ACR, and then also the UC and the CD, which is also a big indication for IL-23. Another thing, the field is definitely moving towards the oral peptide. You're leading that, and then J&J is also benefit from there. How do you think about, we see recent deal related to the long-acting oral peptide. So one is, how you think about that approach, compared to based on what your expertise in this field? And two is Protagonist having some capacity or the capability to do something like that, longer-acting oral peptide?

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day